Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated SIB-IMRT with Temozolomide for High-grade Gliomas
NCT03082846Completed
- Start
- Jan 2014
- Primary completion
- Nov 2016
01
Overview
Open-label, single-arm trial. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jan 2014; status: completed.
Beyond the preview
Go deeper on NCT03082846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082846.